A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Volodymyr V OberemokAnatoly V Kubyshkin

Abstract

Antisense oligonucleotides (ASO), short single-stranded polymers based on DNA or RNA chemistries and synthesized in vitro, regulate gene expression by binding in a sequence-specific manner to an RNA target. The functional activity and selectivity in the action of ASOs largely depends on the combination of nitrogenous bases in a target sequence. This simple and natural property of nucleic acids provides an attractive route by which scientists can create different ASO-based techniques. Over the last 50 years, planned and realized applications in the field of antisense and nucleic acid nanotechnologies have produced astonishing results and posed new challenges for further developments, exemplifying the essence of the post-genomic era. Today the majority of ASOs are chemically modified and/or incorporated within nanoparticles to enhance their stability and cellular uptake. This review critically analyzes some successful cases using the antisense approach in medicine to address severe diseases, such as Duchenne muscular dystrophy and spinal muscular atrophy, and suggests some prospective directions for future research. We also examine in detail the elaboration of unmodified insect-specific DNA insecticides and RNA preparations in th...Continue Reading

References

Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·P C Zamecnik, M L Stephenson
Oct 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·B M PatersonE L Kuff
Sep 11, 1979·Nucleic Acids Research·H Donis-Keller
May 28, 1975·Journal of the American Chemical Society·R I LetsingerN B Lunsford
Jan 1, 1991·Neuromuscular Disorders : NMD·A E Emery
Sep 1, 1985·The Journal of Cell Biology·R Harland, H Weintraub
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·D A Melton
Sep 1, 1983·Cell·R W Simons, N Kleckner
Jun 1, 1997·Antisense & Nucleic Acid Drug Development·C A Stein
Dec 28, 1999·Ocular Immunology and Inflammation·M D de SmetG J van den Horn
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M Gewirtz
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·C WahlestedtJ Wengel
May 12, 2000·Biochimica Et Biophysica Acta·J Summerton
May 12, 2000·Biochimica Et Biophysica Acta·H J LarsenP E Nielsen
Feb 22, 2001·Chemistry & Biology·D A Braasch, D R Corey
Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Jul 31, 2001·Genesis : the Journal of Genetics and Development·B W DraperC B Kimmel
Aug 22, 2001·Lancet·I TammG Hartmann
Apr 25, 2002·Nucleic Acids Research·Jens KurreckVolker A Erdmann
Aug 3, 2002·Science·György Hutvágner, Phillip D Zamore
May 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Andrew Dillin
Dec 10, 2003·Oncogene·Nicholas M Dean, C Frank Bennett
Dec 11, 2003·Microbiology and Molecular Biology Reviews : MMBR·Neema AgrawalSunil K Mukherjee
Jul 11, 2006·Biochimica Et Biophysica Acta·James M Ervasti
Nov 23, 2006·International Journal of Biometeorology·Joel Peter William PittSue Worner
Jul 14, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Arnold Grünweller, Roland K Hartmann
Nov 6, 2007·Nature Biotechnology·James A BaumJames Roberts
Mar 29, 2008·American Journal of Human Genetics·Yimin HuaAdrian R Krainer
Apr 12, 2008·Development·Judith S Eisen, James C Smith
Sep 16, 2008·Molecular Cancer Therapeutics·Jens Bo HansenTroels Koch
Oct 24, 2008·Journal of Cell Science·Julie M Rumble, Colin S Duckett
Nov 1, 2008·Molecular Cancer Therapeutics·Lee M GreenbergerHenrik Ørum

❮ Previous
Next ❯

Citations

Apr 20, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kateryna V LaikovaAnatoly V Kubyshkin
Jul 17, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Marina A Dobrovolskaia, Mark Bathe
Apr 10, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nina BoxbergerUwe K Zettl
Jan 28, 2021·International Journal of Molecular Sciences·Tatyana P MakalishAnatoly V Kubyshkin
Dec 18, 2020·Frontiers in Neurology·Maria MasnataFrancesca Cicchetti
Apr 17, 2020·Advanced Drug Delivery Reviews·Nuphar VeigaDan Peer
Apr 11, 2021·Plant Cell Reports·Uddhab KarkiJianfeng Xu
Sep 28, 2021·Plant Biology·V OberemokR Kamenetsky-Goldstein
Oct 14, 2021·Expert Opinion on Drug Metabolism & Toxicology·Mohammad ShadidAbedelnasser Abulrob

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides
transgenic
transfection
nucleic acid therapies
SMA
gypsy
antisense oligodeoxyribonucleotides

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.